Devices, digital health, and the technology changing how care is delivered.
We are moving into an era where we can finally converse with our data. We can ask, “Why are denials spiking in Region X?” or “Show me the safety profile of this cohort,” and receive an answer, not a spreadsheet. The post Answers at the Speed of Thought: Healthcare Analytics in the Era of Agentic AI appeared first on MedCity News .
It appears Braveheart Bio isn’t going to let Big Pharma take its freedom anytime soon, as the company is aiming for a Nasdaq listing to move its phase 3 cardiovascular drug forward.
You cannot secure what you cannot see, and right now, healthcare organizations are accumulating hidden cyber liabilities with every keystroke. The post Off the Radar: How Unapproved AI Is Complicating Healthcare Cyber Risk appeared first on MedCity News .
Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its lead prostate cancer candidate into phase 3 development with the help of a $315 million series D.
When Axiom's stem cell therapy demonstrated a 0% mortality rate over two years in potentially fatal newborn neurological diseases this week, the biotech's leadership saw a broader validation for their approach to targeting the brain.
Romano, who is joining from rival robotic surgery company Vicarious Surgical, will step into a position that has been held by a series of executives over the past year.
Johnson & Johnson’s MedTech business posted operational sales growth of 3.6% in the second quarter, reaching $8.93 billion, as weaker Abiomed sales weighed on the unit’s performance.
Fairview Health Services turned a $315 million annual loss into a nearly $600 million turnaround in just two years. At the AHA Leadership Summit, CEO James Hereford broke down the strategy behind the comeback, from workforce redesign to frontline-driven process fixes. The post How Fairview Health Services Turned Around a $315M Loss appeared first on MedCity News .
Attovia Therapeutics has filed for an IPO to secure funding for assets, including a potential challenger to Sanofi and Regeneron’s Dupixent and Galderma’s Nemluvio.
The Coalition Against Surprise Medical Billing launched a campaign opposing the No Surprises Act Enforcement Act, arguing it would worsen IDR process abuse. The post Coalition Urges Policymakers to Reject No Surprises Act Enforcement Bill appeared first on MedCity News .
Spero Therapeutics enters immunology with an antibody licensed from Innovent Biologics. The lead indication is a rare autoimmune condition where Spero aims to offer advantages over the Amgen drug that is currently the only approved treatment. The post After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset appeared first on MedCity News .
Every year, the BIO International Convention brings together more than 20,000 leaders from across the global life sciences ecosystem.
After pausing a controversial policy to publicly release drug rejection letters in April, the FDA today confirmed that the pause has been lifted and that more documents will be coming down the line.
Matching the right patient to the right therapy now requires understanding what’s driving the apnea, not just how often it occurs. Closing that gap means rethinking what sleep apnea testing identifies and where it happens. The post Why the Next Era of Sleep Medicine Depends on Better Diagnostics appeared first on MedCity News .
It usually tracks some version of value delivered, where more customers lead to more usage and more revenue. However, in healthcare, the blind pursuit of revenue can cause real harm. The post Revenue Is a Misleading KPI in Healthcare appeared first on MedCity News .
HistoSonics’ phased commercial rollout of the Edison system will initially target centers specializing in liver tumor treatment.
Biogen leaders took to an investor call today to defend the phase 2 readout of the company’s anti-tau Alzheimer’s disease candidate, which, despite slowing cognitive decline on par with approved medicines, sparked a significant stock slip.
In this interview, W. Douglas Weaver MD, MACC and Deepak Bhakta, MD, MBA, FACC discuss managing subclinical AFib detected by devices, ambulatory monitors and wearables.
The PBM reform efforts are directional, not temporary. Meeting these expectations requires automated systems that can reconstruct claim logic on demand and provide real-time alignment between pricing, rebates and financial outputs. The post Pharmacy Benefit Operations Infrastructure Must Rise to Regulatory Reform Standards appeared first on MedCity News .
[Sponsored] This guide is designed to help you identify the environmental constraints that matter most, then address them in a realistic sequence that fits how healthcare IT work actually gets done. The post A Roadmap to Real Healthcare AI Execution appeared first on MedCity News .
Chai Discovery has continued its whirlwind emergence, closing its third financing round in 11 months to bring its total funding haul above $600 million. The latest round values the startup at $3.8 billion.
Summit Therapeutics has cleared out an asset from its pre-ivonescimab history, offloading the antibiotic drug candidate ridinilazole to the OpenAI-backed startup Biossil for $500,000 upfront.
As Kaiser Permanente CEO Greg Adams touted the success of his organization’s value-based care models at the AHA Leadership Summit in Denver, Kaiser nurses outside protested the health system’s AI strategy. They claim they’re being excluded from decisions about the technology. The post Kaiser Nurses Protest CEO’s AHA Appearance Over AI Concerns appeared first on MedCity News .
An ear-based wearable device that taps into the body’s longest cranial nerve boosts blood clotting, which researchers hope could be a new way to treat severe bleeding.